Study of TRPH-222 in Patients With Relapsed and/or Refractory B-Cell Lymphoma

Official Title

Phase 1, Multicentre, Open-Label Study of the Antibody-Drug Conjugate TRPH-222 in Subjects With Relapsed and/or Refractory B-Cell Lymphoma

Summary:

This is a Phase 1, multi-centre, open-label study of TRPH-222 monotherapy in subjects with relapsed and/or refractory B-cell NHL. The study will be conducted in two Stages: Dose-Escalation, Dose-Expansion.

Trial Description

Primary Outcome:

• Maximum Tolerated Dose (MTD)

• Evaluate incidence and severity of AEs, serious AEs, TRPH-222-related AEs, AEs leading to death or discontinuation from treatment
• Tumour Activity
• TRPH-222 Pharmacokinetics (PK)
• TRPH-222 Pharmacokinetics (PK)
• TRPH-222 Pharmacokinetics (PK)
• TRPH-222 Pharmacokinetics (PK)
• TRPH-222 Pharmacokinetics (PK)
• TRPH-222 Pharmacokinetics (PK)

View this trial on ClinicalTrials.gov